OPOSF News 2.9100 Optos Plc (OPOSF)
Post# of 273330
Posted On: 04/17/2014 7:44:53 AM
Optos Plc (OPOSF) 2.9100 $OPOSF
Final Fantasy 14 Debuts China, Operated by Shanda Games
SinoCast - Wed Feb 26, 4:49AM CST
Shanda Games Limited (SDG; Nasdaq: GAME) CEO declared initiation of Chinese operation of Final Fantasy 14 developed by Square Enix. First test will be kicked off in April, marking the debut of the game on China.
Optomap Increases Percentage of Pathology Detected in Conventional Eye Exam
Business Wire - Mon Apr 15, 7:00AM CDT
Optos plc (LSE: OPTS), a world leader in retinal imaging, today announced that the results from a study comparing retinal imaging techniques in 339 eyes conducted at the New England College of Optometry were published in Eye and Brain (1).
OptosOCT/SLO - Retinal Structure and Functional Testing in One Device
Business Wire - Mon Mar 11, 7:00AM CDT
Optos plc (LSE: OPTS), a world leader in retinal imaging, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Microperimetry as part of the OptosOCT SLO. Microperimetry assesses retinal sensitivity providing a precise correlation between structural pathology and corresponding visual functional defects. This data provides more clinical information to support the evaluation of patients' vision.
Final Fantasy 14 Debuts China, Operated by Shanda Games
SinoCast - Wed Feb 26, 4:49AM CST
Shanda Games Limited (SDG; Nasdaq: GAME) CEO declared initiation of Chinese operation of Final Fantasy 14 developed by Square Enix. First test will be kicked off in April, marking the debut of the game on China.
Optomap Increases Percentage of Pathology Detected in Conventional Eye Exam
Business Wire - Mon Apr 15, 7:00AM CDT
Optos plc (LSE: OPTS), a world leader in retinal imaging, today announced that the results from a study comparing retinal imaging techniques in 339 eyes conducted at the New England College of Optometry were published in Eye and Brain (1).
OptosOCT/SLO - Retinal Structure and Functional Testing in One Device
Business Wire - Mon Mar 11, 7:00AM CDT
Optos plc (LSE: OPTS), a world leader in retinal imaging, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Microperimetry as part of the OptosOCT SLO. Microperimetry assesses retinal sensitivity providing a precise correlation between structural pathology and corresponding visual functional defects. This data provides more clinical information to support the evaluation of patients' vision.
(0)
(0)